Skip to content 
Virax Biolabs Group Limited, a biotechnology company, distributes diagnostics test kits for the prevention, detection, diagnosis, and risk management of viral diseases in the field of T cell in Vitro Diagnostics. The company offers various in-vitro diagnostics test kits comprising respiratory, pregnancy and fertility, infectious diseases, sti, drugs of abuse, oncology, cardiac, women's health, other test kits under the ViraxClear brands; and rapid and molecular tests for small animal veterinary diagnostics under the ViraxVet brand. It also provides ViraxImmune, a T cell In vitro diagnostic device and wellness mobile application; and service, such as antibody engineering, custom peptides, protein sequencing, vaccine efficacy testing, immunology lab services, kits and reagents. In addition, the company is involved in research and development activities; and provision of procurement, warehousing, product development, and staffing management services. It serves research organizations, corporations, independent laboratories, large hospital systems and public and private institutions, as well as distributor customers. The company operates in the United Kingdom, the United States, and China. The company was formerly known as Virax Biolabs (Cayman) Limited and changed its name to Virax Biolabs Group Limited in September 2021. Virax Biolabs Group Limited was founded in 2013 and is headquartered in Lanarkshire, the United Kingdom. more
| Time Frame | VRAX | Sector | S&P500 |
|---|---|---|---|
| 1-Week Return | 7.66% | 0.81% | 0.49% |
| 1-Month Return | -21.33% | 1.2% | 1.02% |
| 3-Month Return | -48.86% | 3.24% | 3.34% |
| 6-Month Return | -70.97% | 14.99% | 7.04% |
| 1-Year Return | -87.14% | 7.42% | 11.68% |
| 3-Year Return | -97.04% | 20.71% | 71.63% |
| 5-Year Return | -99.88% | 37.45% | 75.56% |
| Mar '21 | Mar '22 | Mar '23 | Mar '24 | Mar '25 | 5YR TREND | |
|---|---|---|---|---|---|---|
| Total Revenue | 123.82K | - | 8.56K | 156.42K | 6.33K | [{"date":"2021-03-31","value":79.16,"profit":true},{"date":"2022-03-31","value":"-","profit":true},{"date":"2023-03-31","value":5.47,"profit":true},{"date":"2024-03-31","value":100,"profit":true},{"date":"2025-03-31","value":4.05,"profit":true}] |
| Cost of Revenue | 133.25K | - | 9.93K | 105.83K | 59.40K | [{"date":"2021-03-31","value":100,"profit":true},{"date":"2022-03-31","value":"-","profit":true},{"date":"2023-03-31","value":7.45,"profit":true},{"date":"2024-03-31","value":79.42,"profit":true},{"date":"2025-03-31","value":44.58,"profit":true}] |
| Gross Profit | (9.43K) | - | (1.36K) | 50.59K | (53.07K) | [{"date":"2021-03-31","value":-18.65,"profit":false},{"date":"2022-03-31","value":"-","profit":true},{"date":"2023-03-31","value":-2.7,"profit":false},{"date":"2024-03-31","value":100,"profit":true},{"date":"2025-03-31","value":-104.9,"profit":false}] |
| Gross Margin | (7.62%) | - | (15.94%) | 32.34% | (838.21%) | [{"date":"2021-03-31","value":-23.56,"profit":false},{"date":"2022-03-31","value":"-","profit":true},{"date":"2023-03-31","value":-49.3,"profit":false},{"date":"2024-03-31","value":100,"profit":true},{"date":"2025-03-31","value":-2591.65,"profit":false}] |
| Operating Expenses | 635.10K | 1.73M | 5.73M | 6.55M | 6.11M | [{"date":"2021-03-31","value":9.7,"profit":true},{"date":"2022-03-31","value":26.48,"profit":true},{"date":"2023-03-31","value":87.54,"profit":true},{"date":"2024-03-31","value":100,"profit":true},{"date":"2025-03-31","value":93.32,"profit":true}] |
| Operating Income | (644.54K) | (1.73M) | (5.73M) | (6.50M) | (6.16M) | [{"date":"2021-03-31","value":-64454000,"profit":false},{"date":"2022-03-31","value":-173368000,"profit":false},{"date":"2023-03-31","value":-573276000,"profit":false},{"date":"2024-03-31","value":-649647300,"profit":false},{"date":"2025-03-31","value":-616289700,"profit":false}] |
| Total Non-Operating Income/Expense | (57.02K) | (31.63K) | 259.53K | (269.52K) | (99.17K) | [{"date":"2021-03-31","value":-21.97,"profit":false},{"date":"2022-03-31","value":-12.19,"profit":false},{"date":"2023-03-31","value":100,"profit":true},{"date":"2024-03-31","value":-103.85,"profit":false},{"date":"2025-03-31","value":-38.21,"profit":false}] |
| Pre-Tax Income | (672.91K) | (1.75M) | (5.46M) | (6.74M) | (6.20M) | [{"date":"2021-03-31","value":-67291500,"profit":false},{"date":"2022-03-31","value":-174987000,"profit":false},{"date":"2023-03-31","value":-545776300,"profit":false},{"date":"2024-03-31","value":-673912000,"profit":false},{"date":"2025-03-31","value":-620389300,"profit":false}] |
| Income Taxes | (666.47K) | (1.77M) | (271.00) | (194.47K) | (136.66K) | [{"date":"2021-03-31","value":-66646900,"profit":false},{"date":"2022-03-31","value":-177472200,"profit":false},{"date":"2023-03-31","value":-27100,"profit":false},{"date":"2024-03-31","value":-19447400,"profit":false},{"date":"2025-03-31","value":-13666100,"profit":false}] |
| Income After Taxes | (6.45K) | 24.85K | (5.46M) | (6.54M) | (6.07M) | [{"date":"2021-03-31","value":-25.94,"profit":false},{"date":"2022-03-31","value":100,"profit":true},{"date":"2023-03-31","value":-21959.97,"profit":false},{"date":"2024-03-31","value":-26334.48,"profit":false},{"date":"2025-03-31","value":-24413.46,"profit":false}] |
| Income From Continuous Operations | (672.91K) | (1.75M) | (5.46M) | (6.74M) | (6.07M) | [{"date":"2021-03-31","value":-67291500,"profit":false},{"date":"2022-03-31","value":-174987000,"profit":false},{"date":"2023-03-31","value":-545776300,"profit":false},{"date":"2024-03-31","value":-673912000,"profit":false},{"date":"2025-03-31","value":-606723200,"profit":false}] |
| Income From Discontinued Operations | - | - | - | - | - | [{"date":"2021-03-31","value":"-","profit":true},{"date":"2022-03-31","value":"-","profit":true},{"date":"2023-03-31","value":"-","profit":true},{"date":"2024-03-31","value":"-","profit":true},{"date":"2025-03-31","value":"-","profit":true}] |
| Net Income | (650.98K) | (1.71M) | (5.46M) | (6.73M) | (6.06M) | [{"date":"2021-03-31","value":-65098400,"profit":false},{"date":"2022-03-31","value":-170882700,"profit":false},{"date":"2023-03-31","value":-545749400,"profit":false},{"date":"2024-03-31","value":-673353700,"profit":false},{"date":"2025-03-31","value":-606124700,"profit":false}] |
| EPS (Diluted) | - | - | - | - | (0.92) | [{"date":"2021-03-31","value":"-","profit":true},{"date":"2022-03-31","value":"-","profit":true},{"date":"2023-03-31","value":"-","profit":true},{"date":"2024-03-31","value":"-","profit":true},{"date":"2025-03-31","value":-92,"profit":false}] |
These ratios help you determine the liquidity of the company. Higher is better.
| VRAX | |
|---|---|
| Cash Ratio | 9.15 |
| Current Ratio | 11.35 |
| Quick Ratio | 11.21 |
These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.
| VRAX | |
|---|---|
| ROA (LTM) | -48.40% |
| ROE (LTM) | -83.82% |
These ratios help you understand the company's liabilities, gauging the riskiness of the investment.
| VRAX | |
|---|---|
| Debt Ratio Lower is generally better. Negative is bad. | 0.11 |
| Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. | 0.93 |
These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.
| VRAX | |
|---|---|
| Trailing PE | NM |
| Forward PE | NM |
| P/S (TTM) | 541.97 |
| P/B | 0.29 |
| Price/FCF | NM |
| EV/R | 107.17 |
| EV/Ebitda | 0.42 |
Virax Biolabs Group Limited Ordinary Shares (VRAX) share price today is $0.221
Yes, Indians can buy shares of Virax Biolabs Group Limited Ordinary Shares (VRAX) on Vested. To buy
Yes, you can purchase fractional shares of Virax Biolabs Group Limited Ordinary Shares (VRAX) via the Vested app. You can start investing in Virax Biolabs Group Limited Ordinary Shares (VRAX) with a minimum investment of $1.
You can invest in shares of Virax Biolabs Group Limited Ordinary Shares (VRAX) via Vested in three simple steps:
The 52-week high price of Virax Biolabs Group Limited Ordinary Shares (VRAX) is $1.95. The 52-week low price of Virax Biolabs Group Limited Ordinary Shares (VRAX) is $0.2.
The price-to-earnings (P/E) ratio of Virax Biolabs Group Limited Ordinary Shares (VRAX) is
The price-to-book (P/B) ratio of Virax Biolabs Group Limited Ordinary Shares (VRAX) is 0.29
The dividend yield of Virax Biolabs Group Limited Ordinary Shares (VRAX) is 0.00%
The market capitalization of Virax Biolabs Group Limited Ordinary Shares (VRAX) is $1.67M
The stock symbol (or ticker) of Virax Biolabs Group Limited Ordinary Shares is VRAX
Consider the share price of Virax Biolabs Group Limited Ordinary Shares as a long-term story and not a daily point list. The price represents a movement of the stock in both good and bad times when looked at over many years. This assists the investors to know whether Virax Biolabs Group Limited Ordinary Shares has succeeded to expand steadily and overcome market declines. With this price movement observed and the way the business is progressing, it is easier to make a decision whether the stock is worth having in the long term or not.
When investing in Virax Biolabs Group Limited Ordinary Shares shares, you are not based in India then your investment is not just based on the stock price. It is also determined by the currency movement of the dollar in relation to the rupee. When you have an appreciation of the Virax Biolabs Group Limited Ordinary Shares stock and the dollar appreciation is also the same, you gain more in terms of rupees. When the rupee appreciated, it will lower your profits. This currency flow is a silent cause of great contribution to your ultimate returns over many years.
Rather than merely checking the share price of Virax Biolabs Group Limited Ordinary Shares and comparing it with that of other stocks in the same sector, one can check how robust the business is. Investors tend to compare such aspects as profits, cash generation, and the stability of the revenues of the company. This means that Virax Biolabs Group Limited Ordinary Shares stock in most cases does not react in the same manner as other companies in the sector due to its brand and services revenue.
Link copied 
